Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
about
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in miceAxonal conduction block as a novel mechanism of prepulse inhibitionMouse pharmacological models of cognitive disruption relevant to schizophrenia.Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in miceMolecular targets for treating cognitive dysfunction in schizophrenia.Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in ratsScopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands.Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptorsAssessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.Role of the central cholinergic system in the therapeutics of schizophrenia.Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography.Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.Cholinergic modulation of cognitive processing: insights drawn from computational modelsTowards a muscarinic hypothesis of schizophrenia.Cholinergic connectivity: it's implications for psychiatric disorders.Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meetingA neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.Recent advances in treating cognitive impairment in schizophrenia.Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.Pharmacological cognitive enhancement in schizophrenia.Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.The treatment of cognitive impairment in schizophrenia.Can genetics inform the management of cognitive deficits in schizophrenia?Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia.
P2860
Q24645178-629947A8-B80B-44E3-88E5-8235DF2746C4Q30396291-32F7F4EA-6EB6-4FCD-A2A7-94C3E9952CEDQ30396775-63CC4651-4ED1-4B2B-A824-484FAEB16783Q30444290-7E908345-A6C2-4CE7-8D01-22294D8FC84FQ30455140-5C2BFEE5-9B68-46C3-857D-D800B3FC90B4Q30457807-277C8068-7D78-405F-9A74-FE55F5BC8EFAQ30470845-496AC5C1-955D-4B59-8592-25331D77442AQ30484245-892D75B7-BE2A-45FD-AC05-333FD1F813F5Q30491310-B65EAD60-ABE1-4FB7-B19B-6823A9C25291Q30497096-85D05837-4542-404C-B09F-1A17CCB3521FQ33999521-C114F776-054B-45BC-84DA-2608EF64F8E4Q34021750-CFA2F7A1-E752-43EA-AEED-3A019C606EE2Q34128766-9ADEADA2-8A9E-4D55-AAE2-DE83D6DF8365Q34394895-B8BFA0C8-7E55-4A32-8E61-F53AB2519B7AQ34502083-B1FC7080-0505-4946-B25D-AB9717FD626DQ34608625-0B545E72-3287-4DE5-AE93-400CB55FFD61Q34926526-B8E1EEA6-7992-4787-A06A-A5B0ADF8163FQ35675275-C07A2B61-CF28-4D9E-A516-E0AABE4DE8CEQ35748119-D469B0E1-7BED-4465-A923-C151A763E665Q36029534-2575D696-5C81-42FE-939D-096072F2200CQ36673957-BF06087F-04FC-49D3-97BA-EF507DEE32A6Q36812599-E3754D58-99D8-4F4C-9836-6B72B9F9DEDFQ36881172-57A47E75-4039-4DDE-8629-945E9D884298Q37100367-5D846777-ADED-4C25-AA6C-F7FB3BE561C6Q37212798-D3F20A4A-0425-4B58-9B3E-5F3C1E1105A0Q37259258-029C1C08-D216-4B67-B60E-858629F2DB37Q37506679-EB64E734-AD98-40EF-910D-AB05179DDABFQ37511870-3E11CA54-DA01-4E4A-944E-FE0ED97B7825Q37625841-16241A16-BA47-481A-81F2-0DBE5335BF4DQ37813206-39294E3B-0818-4137-8601-99D11BD36F58Q37983548-0AF677C3-1DEB-43CC-A721-B29C592BF590Q38173359-C24D0B24-FEE1-4465-9AB4-A3E0A994F4D2Q38187948-E7FD6C9C-8F73-4BE6-9E57-1B0AFE41387EQ38526546-56561962-172A-481A-9AE5-001C2BAFD121Q38635337-DDE20D1D-F3D8-4CD2-9661-F8B1E709434EQ38647035-2E5FBBAA-E69B-49D3-A65E-0256329C75F2Q39510294-5B4D067C-A018-4DBA-BB25-7C64D89D0389Q40195274-4A87CC14-423F-4342-BFC0-663E513F5B28Q41179447-48477706-6250-4C4B-9344-687E3E3BC2A9Q41295810-11B585B0-A7CE-4B7D-9FED-58CFBA10B7B9
P2860
Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@ast
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@en
type
label
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@ast
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@en
prefLabel
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@ast
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@en
P1433
P1476
Cholinergic targets for cognit ...... itors and muscarinic agonists.
@en
P2093
Joseph I Friedman
P2888
P356
10.1007/S00213-004-1794-X
P577
2004-02-19T00:00:00Z